A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment

AIMS: To assess the safety and efficacy of omarigliptin in subjects with type 2 diabetes mellitus (T2DM) and chronic renal impairment (RI). METHODS: Patients with T2DM with moderate RI (estimated glomerular filtration rate [eGFR] ≥30 to <60 mL/min/1.73 m(2)) (N=114), severe RI (eGFR <30 mL/min...

Descripción completa

Detalles Bibliográficos
Autores principales: Chacra, Antonio, Gantz, Ira, Mendizabal, Geraldine, Durlach, Lucila, O'Neill, Edward A., Zimmer, Zachary, Suryawanshi, Shailaja, Engel, Samuel S., Lai, Eseng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681174/
https://www.ncbi.nlm.nih.gov/pubmed/28449320
http://dx.doi.org/10.1111/ijcp.12955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681174/
https://www.ncbi.nlm.nih.gov/pubmed/28449320
http://dx.doi.org/10.1111/ijcp.12955

Ejemplares similares